Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2000-10-11
2003-05-20
Low, Christopher S. F. (Department: 1653)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S018700, C514S002600, C436S086000, C436S090000, C435S219000, C435S366000, C435S404000, C260S998200
Reexamination Certificate
active
06566338
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is in the field of medicinal chemistry. In particular, the invention relates to the use of caspase inhibitors to treat or prevent non-cancer cell death during chemotherapy and radiation therapy of cancer.
2. Description of Background Art
Organisms eliminate unwanted cells by a process variously known as regulated cell death, programmed cell death or apoptosis. Such cell death occurs as a normal aspect of animal development as well as in tissue homeostasis and aging (Glucksmann, A.,
Biol. Rev. Cambridge Philos. Soc
. 26:59-86 (1951); Glucksmann, A.,
Archives de Biologie
76:419-437 (1965); Ellis et al.,
Dev
. 112:591-603 (1991); Vaux et al.,
Cell
76:777-779 (1994)). Apoptosis regulates cell number, facilitates morphogenesis, removes harmful or otherwise abnormal cells and eliminates cells that have already performed their function. Additionally, apoptosis occurs in response to various physiological stresses, such as hypoxia or ischemia (PCT published application WO6/20721).
There are a number of morphological changes shared by cells experiencing regulated cell death, including plasma and nuclear membrane blebbing, cell shrinkage (condensation of nucleoplasm and cytoplasm), organelle relocalization and compaction, chromatin condensation and production of apoptotic bodies (membrane enclosed particles containing intracellular material) (Orrenius, S.,
J. Internal Medicine
237:529-536 (1995)).
Apoptosis is achieved through an endogenous mechanism of cellular suicide (Wyllie, A. H., in
Cell Death in Biology and Pathology
, Bowen and Lockshin, eds., Chapman and Hall (1981), pp. 9-34). A cell activates its internally encoded suicide program as a result of either internal or external signals. The suicide program is executed through the activation of a carefully regulated genetic program (Wylie et al., Int. Rev. Cyt. 68: 251 (1980); Ellis et al.,
Ann. Rev. Cell Bio
. 7:663 (1991)). Apoptotic cells and bodies are usually recognized and cleared by neighboring cells or macrophages before lysis. Because of this clearance mechanism, inflammation is not induced despite the clearance of great numbers of cells (Orrenius, S.,
J. Internal Medicine
237:529-536 (1995)).
Mammalian interleukin-1&bgr; (IL-1&bgr;) plays an important role in various pathologic processes, including chronic and acute inflammation and autoimmune diseases (Oppenheim, J. H. et. al.
Immunology Today
, 7, 45-56 (1986)). IL-1&bgr; is synthesized as a cell associated precursor polypeptide (pro-IL-1&bgr;) that is unable to bind IL-1 receptors and is biologically inactive (Mosley et al.,
J. Biol. Chem
. 262:2941-2944 (1987)). By inhibiting conversion of precursor IL-1&bgr; to mature IL-1&bgr;, the activity of interleukin-1 can be inhibited. Interleukin-1&bgr; converting enzyme (ICE) is a protease responsible for the activation of interleukin-1&bgr; (IL-1&bgr;) (Thornberry, N. A., et al.,
Nature
356: 768 (1992); Yuan, J., et al.,
Cell
75: 641 (1993)). ICE is a substrate-specific cysteine protease that cleaves the inactive prointerleukin-1 to produce the mature IL-1. The genes that encode for ICE and CPP32 are members of the mammalian ICE/Ced-3 family of genes which presently includes at least twelve members: ICE, CPP32/Yama/Apopain, mICE2, ICE4, ICHl, TX/ICH-2, MCH2, MCH3, MCH4, FLICE/MACH/MCH5, ICE-LAP6 and ICE
re1
III. The proteolytic activity of this family of cysteine proteases, whose active site (a cysteine residue) is essential for ICE-mediated apoptosis, appears critical in mediating cell death (Miura et al.,
Cell
75: 653-660 (1993)). This gene family has recently been named caspases (Alnernri, E. S. et. al.
Cell
, 87, 171 (1996), and Thomberry, N. A. et. al.
J. Biol. Chem
. 272, 17907-17911 (1997)) and divided into three groups according to its known functions. Table 1 summarizes these known caspases.
TABLE 1
Enzyme*
Group I: mediators of inflammation
Caspase-1 (ICE)
Caspase-4 (ICE
rel
-II, TX, ICH-2)
Caspase-5 (ICE
rel
-III, TY)
Group II: effectors of apoptosis
Caspase-2 (ICH-1, mNEDD2)
Caspase-3 (apopain, CPP-32, YAMA)
Caspase-7 (Mch-3, ICE-LAP3, CMH-1)
Group III: activators of apoptosis
Caspase-6 (Mch2)
Caspase-8 (MACH, FLICE, Mch5)
Caspase-9 (ICE-LAP6, Mch6)
Caspase-10
IL-1 is also a cytokine involved in mediating a wide range of biological responses including inflammation, septic shock, wound healing, hematopoiesis and growth of certain leukemias (Dinarello, C. A.,
Blood
77:1627-1652 (1991); diGiovine et al.,
Immunology Today
11:13 (1990)).
WO 93/05071 discloses peptide ICE inhibitors with the formula:
Z-Q
2
-
Asp
-
Q
1
wherein Z is an N-terminal protecting group; Q
2
is 0 to 4 amino acids such that the sequence Q
2
-Asp corresponds to at least a portion of the sequence Ala-Tyr-Val-His-Asp; Q
1
comprises an electronegative leaving group.
WO 96/03982 discloses aspartic acid analogs as ICE inhibitors with the formula:
wherein R
2
is H or alkyl; R
3
is a leaving group such as halogen; R
1
is heteroaryl-CO or an amino acid residue.
U.S. Pat. No. 5,585,357 discloses peptidic ketones as ICE inhibitors with the formula:
wherein n is 0-2; each AA is independently L-valine or L-alanine; R
1
is selected from the group consisting of N-benzyloxycarbonyl and other groups; R
8
, R
9
, R
10
are each independently hydrogen, lower alkyl and other groups.
Mjalli et al. (
Bioorg. Med. Chem. Lett
., 3, 2689-2692, 1993) report the preparation of peptide phenylalkyl ketones as reversible inhibitors of ICE, such as:
Thornberry et al. (
Biochemistry
, 33, 3934-3940, 1994) report the irreversible inactivation of ICE by peptide acyloxymethyl ketones:
wherein Ar is COPh-2,6-(CF
3
)
2
, COPh-2,6-(CH
3
)
2
, Ph-F
5
and other groups.
Dolle et al. (
J. Med. Chem
. 37, 563-564, 1994) report the preparation of P
1
aspartate-based peptide &agr;-((2,6-dichlorobenzoyl)oxy)methyl ketones as potent time-dependent inhibitors of ICE, such as:
Mjalli et al. (
Bioorg. Med. Chem. Lett
., 4, 1965-1968, 1994) report the preparation of activated ketones as potent reversible inhibitors of ICE:
wherein X is NH(CH
2
)
2
, OCO(CH
2
)
2
, S(CH
2
)
3
and other groups.
Dolle et al. (
J. Med. Chem
. 37, 3863-3866, 1994) report the preparation of &agr;-((1-phenyl-3-(trifluoromethyl)-pyrazol-5-yl)oxy)methyl ketones as irreversible inhibitor of ICE, such as:
Mjalli et al. (
Bioorg. Med. Chem. Lett
., 5, 1405-1408, 1995) report inhibition of ICE by N-acyl-Aspartic acid ketones:
wherein XR
2
is NH(CH
2
)
2
Ph, OCO(CH
2
)
2
cyclohexyl and other groups.
Mjalli et al. (
Bioorg. Med. Chem. Lett
., 5, 1409-1414, 1995) report inhibition of ICE by N-acyl-aspartyl aryloxymethyl ketones, such as:
Dolle et al. (
J. Med. Chem
. 38, 220-222, 1995) report the preparation of aspartyl &agr;-((diphenylphosphinyl)oxy)methyl ketones as irreversible inhibitors of ICE, such as:
Graybill et al. (
Bioorg. Med. Chem. Lett
., 7, 41-46, 1997) report the preparation of &agr;-((tetronoyl)oxy)- and &agr;-((tetramoyl)oxy)methyl ketones as inhibitors of ICE, such as:
Semple et al. (
Bioorg. Med. Chem. Lett
., 8, 959-964, 1998) report the preparation of peptidomimetic aminomethylene ketones as inhibitors of ICE, such as:
Okamoto et al. (
Chem. Pharm. Bull
. 47, 11-21, 1999) report the preparation of peptide based ICE inhibitors with the P1 carboxyl group converted to an amide, such as:
EP618223 patent application disclosed inhibitor of ICE as anti-inflammatory agents:
R-A
1
-
A
2
-
X
-
A
3
Wherein R is a protecting group or optionally substituted benzyloxy; A
1
is an &agr;-hydroxy or &agr;-amnino acid residue or a radical of formula:
wherein ring A is optionally substituted by hydroxy or C
1-4
alkoxy and R
a
is CO or CS; A
2
is an &agr;-hydroxy or &agr;-amino acid residue or A
1
and A
2
form together a pseudo-dipeptide or a dipeptide mimetic residue; X is a residue derived from Asp; A
3
is —CH
2
—X
1
—CO—Y
1
, —CH
2
—O—Y
2
, —CH
2
—S—Y
3
, wherein X
1
is O or S; Y
1
, Y
2
or Y
3
is cycloaliphatic residue, and optionally substituted aryl.
WO99/18781 and U.S. Application Ser. No. 09
Green Douglas R.
Mills Gordon B.
Weber Eckard
Cytovia, Inc.
Kam Chih-Min
Low Christopher S. F.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Caspase inhibitors for the treatment and prevention of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Caspase inhibitors for the treatment and prevention of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Caspase inhibitors for the treatment and prevention of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3011042